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tors (c-Jun kinase, ASK1, eIF2α) have 
been implicated in linking ER stress to 
the apoptotic machinery, no coherent 
picture has emerged, making it difficult 
to currently speculate as to the con-
nection between ceramide signaling, 
Akt activation/inactivation, and these 
proapoptotic mediators (Boyce and 
Yuan, 2006).
In sum, the studies by Swanton et 
al. provide extensive new evidence, 
gleaned from diverse experimental 
strategies, that CERT, and its client 
ceramide, are integral to paclitaxel-
mediated cell death. Further, these 
studies identify ER stress as a previ-
ously unrecognized source of signals 
leading to apoptotic cell death upon 
taxane exposure. A challenge posed 
by these studies is to identify which of 
the many biochemical events likely to 
be dysregulated by prolonged mitotic 
checkpoint activity yields the ER stress 
response. An additional challenge is 
to define the mechanism by which ER 
ceramide might regulate taxane sensi-
tivity biochemically and/or pharmaco-
logically. While inhibition of glucosidase 
attenuated the spindle checkpoint by 
conferring mitotic slippage, inserting 
sphingolipid metabolism into this pro-
cess for the first time, there is insuf-
ficient data presented here to ascribe 
such regulation to ER ceramide levels. 
Although these studies probably bring 
up more questions than they answer, 
they do provide unequivocal data that 
signaling associated with ceramide 
metabolism regulates taxane-induced 
apoptosis, the fundamental event in 
taxane-mediated tumor response.
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Oncogenic transcription factors such as PML-RARα, RUNX1-MTG8, and others work in large part 
by the recruitment of inhibitors of gene transcription to target promoters leading to aberrant repres-
sion of gene expression. PML-RARα, an archetypal chimeric oncoprotein, was previously shown to 
bring complexes of histone deacetylases (HDACs), histone methyltransferases (HMTases), and DNA 
methyl transferases (DNMTs) to target genes. In this issue of Cancer Cell, Villa et al. show that the 
full complement of chromatin machinery can be commandeered by these transcription factors with 
the polycomb group of proteins representing the newest identified recruit.The Polycomb Group (PcG) of pro-
teins were initially discovered in 
Drosophila as epigenetic silencers of homeotic (HOX) genes. PcG pro-
teins have since been shown to be 
required for the X chromosome inac-Cancer Cetivation, germline development, stem 
cell renewal, hematopoiesis, and cell 
proliferation.ll 11, June 2007 ©2007 Elsevier Inc. 475
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PreviewsPolycomb proteins form up to 
four different multiprotein Polycomb 
Repressive Complexes (PRCs) 
(Kuzmichev et al., 2005). The PRCs 
alter gene expression by binding to 
and covalently modifying chroma-
tin of target genes. PRC1 consists 
of more than ten subunits including 
BMI-1, which is required for the pro-
liferation and self-renewal of normal 
hematopoietic, leukemia, and neural 
stem cells. This complex possesses a 
histone H2A-K119 ubiquitin E3 ligase 
activity.
PRC2, 3, and 4 contain proteins 
Enhancer of Zeste protein-2 (EZH2), 
Embryonic Ectoderm Develop-
ment (EED), Supressor of Zeste-12 
(SUZ12), and the histone-binding 
proteins RbAP46 and RbAP48. PRC4, 
in addition, contains the NAD+-
dependent HDAC Sirt1, which has 
been implicated in gene silencing. 
There are four different mammalian 
EED proteins that can interact with 
EZH2 and SUZ12 resulting in the dif-
ferent PRC2, 3 and 4 complexes with 
differential histone substrate specifi-
city (Kuzmichev et al., 2005). EZH2, 
the catalytically active component of 
PRC2/3/4, is an HMTase specific for 
histone H3 K27 and histone H1 K26. 
This HMTase activity requires the 
presence of all the other components 
of PRC2/3/4.
PRC complexes may interplay with 
one another. For example, after tri-
methylation of H3K27 by PRC2, 3, 
or 4, PRC1 is recruited to chromatin 
through a chromodomain component 
that recognizes trimethylated H3K27 
where it ubiquitylates H2A-K119 and 
blocks transcription. PRC2-mediated 
trimethylation of H1K26 can be rec-
ognized by the Heterochromatin Pro-
tein 1 (HP1). HP1 has an important 
role in heterochromatin organization, 
maintenance, and gene repression 
by influencing the global structure 
of the chromatin. PRC components 
also interact with other silencing 
machinery. EZH2 can recruit DNMTs 
to PcG repressed genes (Viré et al., 
2006). These proteins hypermethyl-
ate the CpG islands of target genes, 
offering binding sites for methyl cyto-
sine-binding proteins, which in turn 
recruit HDAC complexes. Through all 476 Cancer Cell 11, June 2007 ©2007 Elof these interactions, Polycomb pro-
teins cause condensation of chroma-
tin into higher-order structures unfa-
vorable to gene transcription.
The polycomb complexes have key 
roles in normal development. Com-
ponents of PRC2/3/4 are normally 
expressed at high levels in embryonic 
tissues and stem cells. EZH2 prevents 
stem cell exhaustion and blocks the 
differentiation of muscle myoblast. 
SUZ12 is essential for embryonic 
stem cell differentiation; it has been 
implicated in the formation of consti-
tutive heterochromatin through the 
action of HP1α and the H3K9 HMTase 
SUV39H1 in differentiated murine ES 
cells. In multiple malignancies, aber-
rant expression or recruitment of PcG 
proteins contributes to the reversion 
of normal cells to a more stem cell-
like phenotype. BMI-1 upregulation is 
associated with leukemia, mantle cell 
lymphoma, neuroblastoma, and lung 
cancer. High levels of EZH2 are asso-
ciated with metastatic melanoma 
and endometrium, prostate, and 
breast cancer, as well as lymphoid 
malignancies (Sparmann and van 
Lohuizen, 2006). SUZ12 mRNA is 
upregulated in colon, breast, and liver 
tumors, while in endometrial stromal 
tumors, SUZ12 is fused to the tran-
scription factor JAZF1. The frequent 
upregulation of PRC proteins may be 
due to deregulation of the E2F/Rb 
pathway in malignancy as E2F tran-
scription factors bind and activate the 
promoter of many PRC component 
encoding genes.
The critical targets and pathways 
regulated by PRC complexes remain 
to be fully elucidated. The PRC2 
complex binds to the promoter and 
repress the expression of homeobox 
A9 (HOXA9), a gene frequently over-
expressed in leukemia. How the func-
tion of this complex might be com-
promised in leukemia is uncertain. 
Expression profiling and chromatin 
precipitation identified target genes 
regulated by PRC proteins in normal 
and malignant cells. The recruitment 
of PRC complexes to silenced genes 
is cell type specific (Squazzo et al., 
2006). In embryonal cancer lines, 
PRC components SUZ12 and EZH2 
bind genes implicated in transcrip-sevier Inc.tional regulation, in particular homeo-
domain genes. PRC components and 
associated chromatin modifications 
can be deposited over long stretches 
of the HOX genes of up to 10 kb, sug-
gesting a global role in regulation of 
the gene cluster. By contrast, in adult 
carcinoma cells, a distinct set of tar-
get genes were enriched for encod-
ing glycoproteins, receptors, and 
cell surface proteins with Ig-related 
sequences. In these cells, PRC pro-
tein recruitment and H3K27 trimeth-
ylation was limited to discrete regions 
within the target promoters, implying 
a different mode of recruitment than 
embryonal cells. Polycomb overex-
pression may be linked to specific 
cancer mechanisms. PRC2 binds and 
inhibits expression of hDAB2IP, a Ras 
GTPase activating protein with growth 
inhibitory properties, in prostate can-
cer (Chen et al., 2005) whereas PRCs 
bind to the promoter of MYT1 gene, 
whose Xenopus ortholog induces 
neural differentiation, in colon cancer 
(Kirmizis et al., 2004).
While Drosophila PcG proteins are 
recruited through specific Polycomb 
response elements (PRE), mamma-
lian equivalents to the PRE have not 
been found. PRCs may be tethered 
to promoters through the interaction 
with general transcription factors as 
well as through some specific DNA-
binding proteins. By genome-wide 
location analysis, Bracken et al. (2006) 
found more than 1000 genes bound 
by PcG proteins in human embryonic 
fibroblasts, including ones implicated 
in developmental and signaling path-
ways (e.g. Wnt, TGFb, FGF, Notch, 
and Hedgehog).
Acute Promyelocytic Leukemia 
(APL), defined as the accumulation of 
malignant hematopoietic precursors 
blocked at the stage of the promyelo-
cyte is associated in  98% of cases 
with t(15;17) yielding the PML-RARα 
oncoprotein. PML-RARα has several 
essential properties that distinguish it 
from wild-type Retinoic Acid Recep-
tor α (RARα) (Di Croce, 2005; Quina 
et al., 2006; Licht, 2006) including (1) 
the ability to form homodimers due 
to the dimerization domain of PML. 
This leads to higher affinity for core-
pressors and enhanced recruitment 
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Previewsfigure 1. The fusion Protein PML-RARα Inhibits the expression of RARβ2 Gene 
through Different epigenetic Modifications
The oligomerization of the fusion protein enhances the binding and recruitment of HDACs that 
remove the acetylated group in histones. This modification may be followed by the methylation 
of different histone residues by the HMTase SUV39H1 that methylates H3K9 and by the EZH2 
component of the PRC2/3/4 that methylates H3K27. The polycomb complex recruits DNMTs that 
methylates CpG islands in the RARβ2 promoter. The Methyl-CpG Binding Protein 1 (MBD1) can 
bind to this methylated DNA and may recruit more transcriptional repressors to the chromatin. As 
a result of all these modifications, the transcriptional active chromatin (characterized by the pres-
ence of acetylated histones as well as methylated residues associated with gene activation, such 
as H3K4) becomes inactive. The red circles represent histone methylation, the green rhombuses 
represent histone acetylation, and the orange triangles represent DNA methylation.of histone deacetylases. (2) The 
additional ability to recruit corepres-
sors through interaction with the 
DAX protein, again mediated by the 
PML moiety. (3) The ability to bind to 
DNMT1 and DNMT3a and repressive 
HMTases (SUV39H1). (4) The abil-
ity to bind to widely spaced direct 
repeat sequences in addition to typi-
cal RAR sites. As a result, a multi-
protein complex of PML-RARα may 
bind to typical RAR targets, such 
as the RARβ2 promoter, or to novel 
genes, repress, and even epigeneti-
cally silence such genes through the 
addition of histone and DNA methyl 
marks (Figure 1). This model remains 
incomplete as the target genes criti-
cal for the oncogenic properties 
of the fusion protein remain largely 
unidentified. Nevertheless, treat-
ment of patients with the combina-
tion of all-trans retinoic acid (ATRA) 
and chemotherapy may cure up to 
90% of these patients, due in part to 
the ability of retinoic acid to reverse repression by forcing the release 
of corepressor complexes from the 
fusion protein and stimulating PML-
RARα degradation.
Villa et al. (2007), in this issue of 
Cancer Cell, now demonstrate the 
direct recruitment of PRC2/3/4 by 
PML-RARα protein to its target pro-
moters. PML-RARα copurified with 
H3K27 methylation activity and the 
EED and SUZ12 proteins. Chro-
matin precipitations indicated that 
PML-RARα recruits these proteins, 
along with DNMTs, to alter chroma-
tin configuration and silence expres-
sion of RARα target genes. Further-
more, siRNA-mediated knockdown 
of SUZ12 in NB4 APL cells reversed 
the epigenetic changes mediated by 
PRC2/3/4 (H3K27 di- and trimethyla-
tion as well as DNA methylation) and 
induced differentiation usually seen 
after ATRA treatment of such cells, 
confirming the biological importance 
of polycomb recruitment in the activ-
ity of PML-RARα.Cancer CelThe study of PML-RARα indicated 
the critical role of HDACs in hemato-
logical malignancy and led to a greater 
interest in the discovery of inhibitors 
against these enzymes, most recently 
leading to the approval of vorinostat for 
clinical use. However, HDAC inhibitors 
on their own have little activity in most 
malignancies. The study of the mode of 
action of PML-RARα gives some clue 
as to why: the repression machinery 
brought to genes by fusion oncopro-
teins is complex and, to some extent, 
redundant, using multiple mechanisms 
to silence gene expression. HMTases, 
key components of the polycomb 
complexes, represent another attrac-
tive enigmatic target for transcription 
therapy, and small molecules with rela-
tive selectivity for specific HMTases 
have now been reported (Kubicek et 
al., 2007). Furthermore, polycomb 
components can now be targeted by 
an S-adenosylhomocysteine hydrolase 
inhibitor 3-Deazaneplanocin A (DZNep) 
(Tan et al., 2007). This drug leads to 
the accumulation of adenosylhomo-
cysteine, a metabolite that inhibits 
S-adenosyl-L-methionine-dependent 
methyltransferases, and leads to the 
degradation of the PRC2 components 
EZH2, SUZ12, and EED by an uncer-
tain mechanism. This, in turn, causes 
a decrease in H3K27 methylation spe-
cifically in cancer cells and induces 
apoptosis. Intriguingly, the same PRC2 
depletion effect and changes in H3K27 
methylation was observed after treat-
ment of human primary leukemia cells 
with the hydroxamate HDAC inhibi-
tors LBH589 or LAQ824 (Fiskus et al., 
2006), an effect correlated with the 
induction of apoptosis.
The study of APL and other rela-
tively uncommon forms of hema-
tological malignancy continues to 
yield insight into basic mechanisms 
of normal and aberrant gene regula-
tion. Finding a single agent that can 
reverse these manifold changes, 
such as ATRA, has proven to be 
exceptional. Transcriptional therapy 
with a combination of agents that 
might affect histone acetylation, 
methylation, chromatin remodeling 
and DNA methylation remains an 
exciting possibility already being 
tested in clinical trials.l 11, June 2007 ©2007 Elsevier Inc. 477
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Angiogenesis is a hallmark of solid 
tumors. Disruption of tumor angio-
genesis by blocking proangiogenic 
growth factors or shutdown of the 
established tumor blood vessels 
by vascular targeting agents has 
demonstrated therapeutic effects in 
human cancer. The vascular-disrupt-
ing effect can be mediated directly 
by toxic agents or selectively deliv-
ered by antibody or peptide targeting 
(Neri and Bicknell, 2005). The recent 
successful blockade of the VEGF 
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prolonged survival in phase III clinical 
trials and has encouraged the iden-
tification of new tumor endothelial 
markers (TEMs).
Early attempts to identify tumor 
vascular targets focused on the study 
of in vitro endothelial cell (EC)-iso-
lates using a range of molecular, 
biochemical, and immunological 
techniques. These efforts have led to 
the identification of a limited number 
of molecular markers predominantly 
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